{"id":"epirubicin-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity / congestive heart failure"},{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin is an anthracycline chemotherapy agent that works by intercalating into the DNA double helix and inhibiting topoisomerase II, an enzyme essential for DNA replication and transcription. This prevents the separation of DNA strands and leads to accumulation of DNA breaks, triggering apoptosis in cancer cells. It is commonly used in combination chemotherapy regimens for solid tumors.","oneSentence":"Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:16.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (adjuvant and metastatic)"},{"name":"Gastric cancer"},{"name":"Ovarian cancer"},{"name":"Lymphomas"}]},"trialDetails":[{"nctId":"NCT07449949","phase":"","title":"A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma","status":"ENROLLING_BY_INVITATION","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-10-30","conditions":"ORR, PFS, OS","enrollment":43},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT06844357","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","status":"RECRUITING","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2025-03-27","conditions":"HCC","enrollment":300},{"nctId":"NCT05024734","phase":"PHASE2","title":"Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids","status":"RECRUITING","sponsor":"Roland Seiler-Blarer","startDate":"2023-02-21","conditions":"Bladder Cancer, Non-muscle Invasive","enrollment":34},{"nctId":"NCT06848556","phase":"PHASE1, PHASE2","title":"Evaluate the Effect of Tirazamine on Primary Liver Cancer.","status":"TERMINATED","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2021-05-14","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":16},{"nctId":"NCT06705127","phase":"PHASE2","title":"Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-01","conditions":"HR-positive,HER2-negative Breast Cancer","enrollment":30},{"nctId":"NCT06389006","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-29","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT06227065","phase":"PHASE2","title":"Precise Neoadjuvant Chemoresection of Low Grade NMIBC","status":"NOT_YET_RECRUITING","sponsor":"University of Bern","startDate":"2024-10","conditions":"Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low-risk","enrollment":28},{"nctId":"NCT05983094","phase":"PHASE2","title":"Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-01","conditions":"Breast Cancer, Neoadjuvant Therapy","enrollment":181},{"nctId":"NCT04433156","phase":"PHASE2","title":"VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2020-04-22","conditions":"Marginal Zone Lymphoma","enrollment":60},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT05420454","phase":"PHASE4","title":"A Study for the Neoadjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":1576},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT05204524","phase":"NA","title":"Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-08-27","conditions":"Leiomyosarcoma","enrollment":28},{"nctId":"NCT04059003","phase":"","title":"CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2019-11-01","conditions":"Breast Neoplasms","enrollment":200},{"nctId":"NCT02535221","phase":"PHASE3","title":"Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer","status":"RECRUITING","sponsor":"Peking University","startDate":"2015-07-29","conditions":"Breast Cancer","enrollment":234},{"nctId":"NCT05053386","phase":"NA","title":"Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10","conditions":"Hepatocellular Carcinoma","enrollment":186},{"nctId":"NCT04213898","phase":"PHASE1, PHASE2","title":"SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2020-01","conditions":"Triple-negative Breast Cancer","enrollment":39},{"nctId":"NCT03251768","phase":"PHASE2","title":"Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-10-19","conditions":"Chemotherapy-induced Neutropenia","enrollment":80},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT03755115","phase":"PHASE2","title":"SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-02-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":40},{"nctId":"NCT02767674","phase":"PHASE3","title":"Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":258},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT02465801","phase":"PHASE2","title":"Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2014-12-16","conditions":"Chemotherapy-induced Neutropenia","enrollment":216},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT00123318","phase":"PHASE3","title":"A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-02","conditions":"Gastric Cancer","enrollment":52},{"nctId":"NCT01428414","phase":"PHASE2","title":"Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Zhimin Shao","startDate":"2011-08","conditions":"HER-2 Positive Breast Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epirubicin Injectable Product","genericName":"Epirubicin Injectable Product","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells. Used for Breast cancer (adjuvant and metastatic), Gastric cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}